Search results
Results from the Think 24/7 Content Network
MDAI ( 5,6-methylenedioxy-2-aminoindane) is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non- neurotoxic and highly selective serotonin releasing agent (SSRA) in vitro and produces entactogen effects in humans.
3,4-Methylenedioxyamphetamine (also known as MDA and sass) is an empathogen-entactogen, psychostimulant, and psychedelic drug of the amphetamine family that is encountered mainly as a recreational drug. In its pharmacology, MDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA). In most countries, the drug is a controlled ...
David Earl Nichols (born December 23, 1944, Covington, Kentucky) is an American pharmacologist and medicinal chemist. [1] Previously the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology at Purdue University, Nichols has worked in the field of psychoactive drugs since 1969. While still a graduate student, he patented the ...
2-Aminoindane ( 2-AI) is a research chemical with applications in neurologic disorders and psychotherapy that has also been sold as a designer drug. [1] It acts as a selective substrate for NET and DAT. [2] [3]
Also published as Evening Capital, 1884-1981 and Evening Capital and Maryland Gazette, 1910-1922. Also published as The Times, 1911-1956. Also published as The Crescent, 1893-1898, The Times Crescent, 1898-1966, The Times-Crescent The Charles County Leaf, 1966-1971, Times-Crescent, 1971-1989.
Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL
5-Iodo-2-aminoindane ( 5-IAI) is a drug which acts as a releasing agent of serotonin, norepinephrine, and dopamine. [ 2] It was developed in the 1990s by a team led by David E. Nichols at Purdue University. [ 3] 5-IAI fully substitutes for MDMA in rodents and is a putative entactogen in humans. [ 3] Unlike related aminoindane derivatives like ...
MDMAI. 5,6-Methylenedioxy-N-methyl-2-aminoindane ( MDMAI ), is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non- neurotoxic and highly selective serotonin releasing agent (SSRA) in animals and a putative entactogen in humans. [1]